ZIVO BIOSCIENCE INC - ZIVO STOCK NEWS

Welcome to our dedicated page for ZIVO BIOSCIENCE news (Ticker: ZIVO), a resource for investors and traders seeking the latest updates and insights on ZIVO BIOSCIENCE stock.

ZIVO Bioscience Inc. is a U.S.-based research and development firm focusing on natural nutritional compounds and bioactive molecules from proprietary algal strains. The company is committed to studying, developing, and commercializing these innovative products.

08/23/2024 11:39 AM

News

ZIVO Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler Chickens

Rhea-AI Summary

ZIVO Bioscience, Inc. (OTCQB: ZIVO) reports favorable results from a 42-day study of its coccidiosis treatment in broiler chickens. The study, conducted with a major global animal health company, showed that ZIVO's non-antibiotic, immune-modulating product significantly improved growth performance and reduced clinical signs of disease when used in combination with existing treatments. Chickens treated with ZIVO's product alongside an ionophore or vaccination achieved feed conversion ratios comparable to healthy, uninfected birds. This demonstrates the product's potential to enhance current treatment options and its standalone treatment capabilities for coccidiosis, a major challenge in poultry production.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.71%

Tags

07/08/2024 08:00 AM

News

Major Global Animal Health Company Launches 42-Day Confirmatory Study with ZIVO Bioscience’s Coccidiosis Treatment in Broiler Chickens

Rhea-AI Summary

ZIVO Bioscience (NASDAQ: ZIVO) announced the start of a 42-day confirmatory study in partnership with a major global animal health company to validate its non-antibiotic coccidiosis treatment for broiler chickens. This study, building on previous positive results, aims to ensure the product's effectiveness under commercial poultry production conditions. The study compares ZIVO's product with traditional ionophore-based treatments and explores combinations with coccidiosis vaccines. The goal is to provide a sustainable, antibiotic-free solution to address the $10 billion annual loss in the poultry industry due to coccidiosis. The results are expected by September.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-11.76%

Tags

02/07/2024 04:54 PM

News

ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study

Rhea-AI Summary

Zivo Bioscience, Inc. announces positive findings from a 42-day coccidiosis challenge study, demonstrating the impact of its product on broiler production. The product reduces intestinal damage caused by the Eimeria parasite, leading to improved feed utilization and a better Feed Conversion Ratio (FCR), which drives profitability. These results position ZIVO's product as a potential game-changer in the poultry industry, offering improved outcomes at cost parity or better.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.1%

Tags

01/29/2024 08:00 AM

News

ZIVO Bioscience Announces Uplisting to OTCQB Market

Rhea-AI Summary

Zivo Bioscience, Inc. (ZIVO) has successfully uplisted its common stock from the OTC Pink Market to the OTCQB Venture Market, under the ticker symbol 'ZIVO'. This move is aimed at enhancing visibility, improving market access, and increasing liquidity for shareholders. The OTCQB listing requires compliance with higher standards, financial reporting with the SEC, minimum bid price test, audited financials, and company verification.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.6%

Tags

01/23/2024 08:00 AM

News

ZIVO Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

Rhea-AI Summary

Zivo Bioscience, Inc. announces positive results from a 42-day coccidiosis challenge study, demonstrating the effectiveness of its immune-modulating treatment for broiler chickens. The study showed that the product candidate is comparable to a market-leading anticoccidial product containing antibiotics and chemicals. Zivo will pursue a partnership with a global animal health company for commercializing its coccidiosis product.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

18.74%

Tags

10/30/2023 08:30 AM

News

ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

Rhea-AI Summary

Zivo Bioscience, Inc. is conducting a 42-day study to validate the efficacy of its immune-modulating treatment for coccidiosis in broiler chickens. The study aims to confirm the positive effects of Zivo's non-antibiotic alternative, including reduced mortality and improved bird growth rates. The study will also analyze secondary benefits such as protection of intestinal tissue and reduction of pathogenic bacteria.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.89%

Tags

10/26/2023 08:30 AM

News

ZIVO Bioscience Announces Reverse Stock Split

Rhea-AI Summary

Zivo Bioscience announces a 1-for-6 reverse stock split to regain compliance with Nasdaq listing requirements.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-11.11%

Tags

10/03/2023 08:30 AM

News

ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference

Rhea-AI Summary

Zivo Bioscience, Inc. announces participation in the 8th Annual Dawson James Small Cap Growth Conference.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

10.94%

Tags

09/19/2023 04:15 PM

News

Trial Results Confirm Efficacy of ZIVO Bioscience’s Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens

Rhea-AI Summary

ZIVO Bioscience announces positive results from coccidiosis trial in broiler chickens, demonstrating statistically significant improvements in broiler health. The product candidate showed potential to mitigate the effects of coccidiosis through a non-antibiotic mechanism of action. ZIVO plans to launch the final phase of validation with results expected by the end of 2023. The company remains confident in the stability and effectiveness of its product candidate, presenting a disruptive solution to coccidiosis in the poultry industry.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

4.29%

Tags

08/16/2023 08:30 AM

News

ZIVO Announces Commitment by ZWorldwide to Purchase all Zivolife™ Algal Biomass Product Produced Over the Next 18 Months

Rhea-AI Summary

Zivo Bioscience, Inc. announces that ZWorldwide, its exclusive distributor in North America, will purchase the entire supply of Zivolife for the first 18 months. ZWorldwide has also committed to purchasing at least 24,000 kilograms of product for each of the next five years. ZIVO is collaborating with Alimenta Algae to increase production volumes and expects a new facility to be fully operational in 2025, capable of producing up to 100,000 kilograms of dried product per year.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.55%

Tags

FAQ

What is the current stock price of ZIVO BIOSCIENCE (ZIVO)?

The current stock price of ZIVO BIOSCIENCE (ZIVO) is $20 as of October 15, 2024.

What is the market cap of ZIVO BIOSCIENCE (ZIVO)?

The market cap of ZIVO BIOSCIENCE (ZIVO) is approximately 68.3M.

What is ZIVO Bioscience Inc.?

ZIVO Bioscience Inc. is a U.S.-based research and development firm specializing in natural nutritional compounds and bioactive molecules derived from proprietary algal strains.

What is the primary focus of ZIVO Bioscience Inc.?

The company is dedicated to studying, developing, and commercializing natural nutritional compounds and bioactive molecules from their exclusive algal strains.

What sets ZIVO Bioscience Inc. apart from others?

ZIVO Bioscience Inc. stands out for its focus on natural nutritional compounds and bioactive molecules sourced from proprietary algal strains, showcasing innovation and sustainability in its products.

What is the core business of ZIVO Bioscience Inc.?

The core business of ZIVO Bioscience Inc. is the research, development, and commercialization of natural nutritional compounds and bioactive molecules from unique algal strains.

How does ZIVO Bioscience Inc. contribute to the industry?

ZIVO Bioscience Inc. contributes to the industry through its pioneering work on natural nutritional compounds and bioactive molecules, offering sustainable and innovative solutions.

What are the recent achievements of ZIVO Bioscience Inc.?

Recent achievements of ZIVO Bioscience Inc. include advancements in the study and development of natural nutritional compounds and bioactive molecules from proprietary algal strains.

Does ZIVO Bioscience Inc. have any partnerships?

ZIVO Bioscience Inc. may have partnerships within the industry to further research, develop, and commercialize natural nutritional compounds and bioactive molecules from their exclusive algal strains.

What products does ZIVO Bioscience Inc. offer?

ZIVO Bioscience Inc. offers products derived from natural nutritional compounds and bioactive molecules sourced from their proprietary algal strains, showcasing unique and sustainable solutions.

How is ZIVO Bioscience Inc.'s financial condition?

ZIVO Bioscience Inc.'s financial condition may vary based on its research, development, and commercialization efforts related to natural nutritional compounds and bioactive molecules from exclusive algal strains.

What projects is ZIVO Bioscience Inc. currently working on?

ZIVO Bioscience Inc. is currently working on projects related to the study, development, and commercialization of natural nutritional compounds and bioactive molecules from their specialized algal strains.